Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Recent advances in the discovery of small molecules targeting glioblastoma.

Fernandes GFDS, Fernandes BC, Valente V, Dos Santos JL.

Eur J Med Chem. 2019 Feb 15;164:8-26. doi: 10.1016/j.ejmech.2018.12.033. Epub 2018 Dec 16. Review.

PMID:
30583248
2.

BET bromodomain proteins are required for glioblastoma cell proliferation.

Pastori C, Daniel M, Penas C, Volmar CH, Johnstone AL, Brothers SP, Graham RM, Allen B, Sarkaria JN, Komotar RJ, Wahlestedt C, Ayad NG.

Epigenetics. 2014 Apr;9(4):611-20. doi: 10.4161/epi.27906. Epub 2014 Feb 19.

3.

Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.

Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP.

Mol Cancer. 2017 Jun 7;16(1):100. doi: 10.1186/s12943-017-0670-3. Review.

4.

Current Challenges and Opportunities in Treating Glioblastoma.

Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N.

Pharmacol Rev. 2018 Jul;70(3):412-445. doi: 10.1124/pr.117.014944.

5.

Epigenetic pathways and glioblastoma treatment.

Clarke J, Penas C, Pastori C, Komotar RJ, Bregy A, Shah AH, Wahlestedt C, Ayad NG.

Epigenetics. 2013 Aug;8(8):785-95. doi: 10.4161/epi.25440. Epub 2013 Jun 27. Review.

6.

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.

Jiang P, Mukthavaram R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, Kesari S.

J Transl Med. 2014 Jan 17;12:13. doi: 10.1186/1479-5876-12-13. Erratum in: J Transl Med. 2014;12:126. Mukthavavam, Rajesh [corrected to Mukthavaram, Rajesh].

7.

Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma.

Liu Z, Li H, He L, Xiang Y, Tian C, Li C, Tan P, Jing J, Tian Y, Du L, Huang Y, Han L, Li M, Zhou Y.

Cell Chem Biol. 2018 Nov 30. pii: S2451-9456(18)30431-8. doi: 10.1016/j.chembiol.2018.11.009. [Epub ahead of print]

PMID:
30639261
8.

Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.

Zhu P, Zhu JJ.

Chin Clin Oncol. 2017 Aug;6(4):41. doi: 10.21037/cco.2017.06.29. Review.

9.

Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells.

Daniele S, Pietrobono D, Costa B, Giustiniano M, La Pietra V, Giacomelli C, La Regina G, Silvestri R, Taliani S, Trincavelli ML, Da Settimo F, Novellino E, Martini C, Marinelli L.

ACS Chem Neurosci. 2018 Jan 17;9(1):85-99. doi: 10.1021/acschemneuro.7b00023. Epub 2017 Apr 11.

PMID:
28368610
10.

A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling.

Yang F, Nam S, Brown CE, Zhao R, Starr R, Ma Y, Xie J, Horne DA, Malkas LH, Jove R, Hickey RJ.

PLoS One. 2014 Apr 14;9(4):e94443. doi: 10.1371/journal.pone.0094443. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e100708. Ma, Yuelong [added]; Xie, Jun [added].

11.

Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.

Clark PA, Bhattacharya S, Elmayan A, Darjatmoko SR, Thuro BA, Yan MB, van Ginkel PR, Polans AS, Kuo JS.

J Neurosurg. 2017 May;126(5):1448-1460. doi: 10.3171/2016.1.JNS152077. Epub 2016 Jul 15.

12.

Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.

William D, Walther M, Schneider B, Linnebacher M, Classen CF.

PLoS One. 2018 Jan 19;13(1):e0191511. doi: 10.1371/journal.pone.0191511. eCollection 2018.

13.

Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.

Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, Watanabe R, Mitsuya K, Matsuno K, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A, Nakasu Y, Yamaguchi K, Akiyama Y.

Int J Oncol. 2013 Jul;43(1):219-27. doi: 10.3892/ijo.2013.1916. Epub 2013 Apr 23.

PMID:
23612755
14.

Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.

Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH.

Cancer Lett. 2015 Dec 1;369(1):250-8. doi: 10.1016/j.canlet.2015.08.022. Epub 2015 Sep 2.

15.

Analysis of Chemopredictive Assay for Targeting Cancer Stem Cells in Glioblastoma Patients.

Howard CM, Valluri J, Alberico A, Julien T, Mazagri R, Marsh R, Alastair H, Cortese A, Griswold M, Wang W, Denning K, Brown L, Claudio PP.

Transl Oncol. 2017 Apr;10(2):241-254. doi: 10.1016/j.tranon.2017.01.008. Epub 2017 Feb 12.

16.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
17.

The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture.

Haley EM, Kim Y.

Cancer Lett. 2014 Apr 28;346(1):1-5. doi: 10.1016/j.canlet.2013.12.003. Epub 2013 Dec 11. Review.

18.

Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.

Song WS, Yang YP, Huang CS, Lu KH, Liu WH, Wu WW, Lee YY, Lo WL, Lee SD, Chen YW, Huang PI, Chen MT.

J Chin Med Assoc. 2016 Oct;79(10):538-45. doi: 10.1016/j.jcma.2016.03.010. Epub 2016 Aug 13.

19.

Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design.

Masoumi S, Harisankar A, Gracias A, Bachinger F, Fufa T, Chandrasekar G, Gaunitz F, Walfridsson J, Kitambi SS.

Drug Des Devel Ther. 2016 Sep 12;10:2881-2897. eCollection 2016.

20.

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

de Paula LB, Primo FL, Tedesco AC.

Biophys Rev. 2017 Oct;9(5):761-773. doi: 10.1007/s12551-017-0293-3. Epub 2017 Aug 19. Review.

Supplemental Content

Support Center